相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
G. Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Daniel D. Mikol et al.
LANCET NEUROLOGY (2008)
The presence and meaning of chronic sorrow in patients with multiple sclerosis
Ann-Kristin Isaksson et al.
JOURNAL OF CLINICAL NURSING (2007)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
D. S. Goodin et al.
NEUROLOGY (2007)
Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays
Amer Jaber et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2007)
Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
A. Sominanda et al.
MULTIPLE SCLEROSIS (2007)
Anxiety disorders and their clinical correlates in multiple sclerosis patients
M. Korostil et al.
MULTIPLE SCLEROSIS (2007)
Prediction of anxiety and distress following diagnosis of multiple sclerosis:: a two-year longitudinal study
A. C. J. W. Janssens et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
L. Kappos et al.
NEUROLOGY (2006)
Depression and multiple sclerosis: Review of a lethal combination
Mitchell T. Wallin et al.
JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT (2006)
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
CC Ford et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial
H Panitch et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
Estimating long-term effects of disease-modifying drug, therapy in multiple sclerosis patients
RA Rudick et al.
MULTIPLE SCLEROSIS (2005)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: The PRISMS study
J Oger et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2005)
The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis:: 4-year data from the PRISMS study
R Gold et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Results following development of neutralizing antibodies in PRISMS
GS Francis et al.
NEUROLOGY (2005)
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis - The EVIDENCE study
SR Schwid et al.
ARCHIVES OF NEUROLOGY (2005)
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis
O Andersen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2004)
Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy
L Durelli et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2004)
Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFN beta-1a Dose-Comparison Study
M Clanet et al.
MULTIPLE SCLEROSIS (2004)
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
M Filippi et al.
LANCET (2004)
Diagnosis of multiple sclerosis:: comparison of the Poser criteria and the new McDonald criteria
T Fangerau et al.
ACTA NEUROLOGICA SCANDINAVICA (2004)
Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
DS Goodin et al.
NEUROLOGY (2002)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
WI McDonald et al.
ANNALS OF NEUROLOGY (2001)
Randomized controlled trial of interferon-beta-1a in secondary progressive MS - MRI results
DKB Li et al.
NEUROLOGY (2001)
Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study
G Comi et al.
LANCET (2001)
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
KP Johnson et al.
MULTIPLE SCLEROSIS JOURNAL (2000)
分享论文
